Technical Analysis for APRE - Aprea Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.26% | |
| Down 3 Days in a Row | Weakness | 0.26% | |
| Gapped Down | Weakness | 0.26% | |
| Outside Day | Range Expansion | -2.24% | |
| Wide Bands | Range Expansion | -2.24% | |
| Wide Bands | Range Expansion | -7.76% |
| Alert | Time |
|---|---|
| Down 1% | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| 10 DMA Resistance | about 20 hours ago |
| Up 5% | about 20 hours ago |
| Up 3% | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.1501 |
| Average Volume | 24,869 |
| 200-Day Moving Average | 4.73 |
| 50-Day Moving Average | 3.30 |
| 20-Day Moving Average | 3.58 |
| 10-Day Moving Average | 4.07 |
| Average True Range | 0.37 |
| RSI (14) | 57.81 |
| ADX | 34.05 |
| +DI | 24.96 |
| -DI | 16.79 |
| Chandelier Exit (Long, 3 ATRs) | 3.89 |
| Chandelier Exit (Short, 3 ATRs) | 3.27 |
| Upper Bollinger Bands | 5.02 |
| Lower Bollinger Band | 2.14 |
| Percent B (%b) | 0.62 |
| BandWidth | 80.56 |
| MACD Line | 0.27 |
| MACD Signal Line | 0.25 |
| MACD Histogram | 0.0176 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.36 | ||||
| Resistance 3 (R3) | 4.38 | 4.27 | 4.28 | ||
| Resistance 2 (R2) | 4.27 | 4.16 | 4.25 | 4.26 | |
| Resistance 1 (R1) | 4.09 | 4.09 | 4.18 | 4.07 | 4.23 |
| Pivot Point | 3.98 | 3.98 | 4.02 | 3.96 | 3.98 |
| Support 1 (S1) | 3.80 | 3.87 | 3.89 | 3.78 | 3.61 |
| Support 2 (S2) | 3.69 | 3.80 | 3.67 | 3.58 | |
| Support 3 (S3) | 3.51 | 3.69 | 3.56 | ||
| Support 4 (S4) | 3.49 |
